Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2012
03/01/2012US20120052096 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
03/01/2012US20120052095 Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
03/01/2012US20120052040 Polymer compositions and methods for their use
03/01/2012US20120052022 Composition for oral health treatment and related methods of use
03/01/2012US20120052021 Inhibition of undesired sensory effects by the compound camphor
03/01/2012US20120052019 Certain chemical entities, compositions, and methods
03/01/2012US20120052012 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012US20120052007 Peripheral blood sparc binding antibodies and uses thereof
03/01/2012US20120052006 Gold/lanthanide nanoparticle conjugates and uses thereof
03/01/2012US20120051828 Soft edge pad
03/01/2012US20120048764 Process to form an orally disintegrating tablet for human use
03/01/2012DE102010005124A1 Feste pharmazeutische Zusammensetzung umfassend Lercanidipin A solid pharmaceutical composition comprising lercanidipine
03/01/2012CA2809415A1 Cell-protective peptides and uses thereof
03/01/2012CA2809263A1 Pharmaceutical composition and administrations thereof
03/01/2012CA2809228A1 Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles
03/01/2012CA2808978A1 Compositions for gastric delivery of active agents
03/01/2012CA2808872A1 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012CA2808501A1 Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
03/01/2012CA2808282A1 Improved enteric active substance delivery
03/01/2012CA2808225A1 Compositions and methods for cardiac therapy
03/01/2012CA2807968A1 Salt compound
03/01/2012CA2805602A1 Humidified particles comprising a therapeutically active substance
03/01/2012CA2796755A1 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
02/2012
02/29/2012EP2423213A1 Preparation and use of novel antibiotic, anticancer compounds and derivatives thereof
02/29/2012EP2422816A1 A drug composition for treating tumor with polymeric micelle encapsulating antineoplastic
02/29/2012EP2422804A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
02/29/2012EP2422783A1 Pharmaceutical Composition
02/29/2012EP2422776A1 Polyarginine nanocapsules
02/29/2012EP2422775A2 Sequestering subunit and related compositions and methods
02/29/2012EP2422774A1 Pharmaceutical composition containing a tetrahydrofolic acid
02/29/2012EP2422773A2 Sequestering subunit and related compositions and methods
02/29/2012EP2422772A2 Sequestering subunit and related compositions and methods
02/29/2012EP2422771A1 Tablet and pestles therefor
02/29/2012EP2422770A1 Formulations of peg-interferon alpha conjugates
02/29/2012EP2422769A1 Compositions and methods for improved organ transplant preservation and acceptance
02/29/2012EP2422768A2 Penetrating pharmaceutical foam
02/29/2012EP2422767A2 Methods for preparing dry powder compositions of glycopyrrolate
02/29/2012EP2422766A2 Methods for preparing dry powder compositions of glycopyrrolate
02/29/2012EP2422765A1 Ophthalmic compositions and methods for treating eyes
02/29/2012EP2421601A2 Method for transdermal iontophoretic delivery of chelated agents
02/29/2012EP2421560A2 Delivery systems
02/29/2012EP2421551A2 Silk fibroin hydrogels and uses thereof
02/29/2012EP2421540A1 A novel formulation of meloxicam
02/29/2012EP2421539A1 Methods of treating a pulmonary bacterial infection using fluoro-quinolones
02/29/2012EP2421534A1 Liquid formulations of salts of 1-ý2-(2,4-dimethylphenylsulfanyl)phenyl¨piperazine
02/29/2012EP2421531A1 Use of nifuratel to treat infections caused by atopobium species
02/29/2012EP2421530A1 A novel formulation of metaxalone
02/29/2012EP2421525A1 A novel formulation of diclofenac
02/29/2012EP2421522A1 Paracetamol for parenteral administration
02/29/2012EP2421521A1 Stable topical compositions for 1,2,4-thiadiazole derivatives
02/29/2012EP2421518A2 Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
02/29/2012EP2421517A2 Controlled release dispensing device
02/29/2012EP2421516A1 Method for improving the dissolution profile of a biologically active material
02/29/2012EP2421515A2 Particulate pharmaceutical composition having an opioid and an opioid antagonist
02/29/2012EP2421514A2 Agglomerate formulations useful in dry powder inhalers
02/29/2012EP2421513A1 A novel formulation of indomethacin
02/29/2012EP2421512A1 A novel formulation of naproxen
02/29/2012EP2421511A1 Method for the production of commercial nanoparticle and microparticle powders
02/29/2012EP2421510A1 Production of encapsulated nanoparticles at commercial scale
02/29/2012EP2421509A1 Production of encapsulated nanoparticles at high volume fractions
02/29/2012EP2421508A1 Particulate material for controlled release of active ingredients
02/29/2012EP2421507A1 Chewing gum and particulate material for controlled release of active ingredients
02/29/2012EP2421506A2 Nanocarrier therapy for treating invasive tumors
02/29/2012EP2421505A2 Hydrogels for combinatorial delivery of immune-modulating biomolecules
02/29/2012EP2421504A1 Paediatric solutions comprising a beta-blocker
02/29/2012EP2421503A1 Sublingual pharmaceutical composition comprising a neutral oil
02/29/2012EP2421496A1 Emulsions for transdermal delivery
02/29/2012EP2421494A2 Method for producing free powder particles of polyamide impregnated with at least one cosmetic or pharmaceutical agent, and free powder particles of polyamide having a content of at least 25 wt % of at least one cosmetic or pharmaceutical agent
02/29/2012EP2421373A1 Colon lavage system
02/29/2012EP2421367A1 Allantoin administration for the treatment of neurodegenerative disease and neurotrauma
02/29/2012EP2180795B1 Delivery and controlled release of encapsulated lipophilic nutrients
02/29/2012EP1954241B1 Sustained-release formulation of zonisamide
02/29/2012EP1871341B1 Charged lipoprotein complexes and their uses
02/29/2012EP1853308B1 Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter
02/29/2012EP1849830B1 Finely divided composition containing poorly water soluble substance
02/29/2012EP1735005B1 Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability
02/29/2012EP1633800B9 Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications
02/29/2012EP1625850B1 Immunostimulating agents
02/29/2012EP1499302B1 Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
02/29/2012EP1480677B1 Composition for stabilizing hyaluronic acid
02/29/2012EP1390383B1 Antisense permeation enhancers
02/29/2012EP1338275B1 Pharmaceutical composition, the use thereof and method for producing said composition
02/29/2012CN202151439U 一种方便服用的麝香保心丸 A convenient taking HMP
02/29/2012CN1972678B Steroid intraocular implants having an extended sustained release for a period of greater than two months
02/29/2012CN1929819B Rapidly dissolving film for delivery of an active agent
02/29/2012CN1921888B Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
02/29/2012CN1921814B Abuse resistance opioid transdermal delivery device and its pharmaceutical use
02/29/2012CN1878540B Taste masked pharmaceutical composition comprising pH sensitive polymer
02/29/2012CN1874756B Pharmaceutical metered dose inhaler and methods relating thereto
02/29/2012CN1842325B Dosage form
02/29/2012CN1703200B Sequestering subunit and related compositions and methods
02/29/2012CN1447698B Flavone-containing plant extract solutions having improved storage and head stability
02/29/2012CN102365110A Binary and tertiary galvanic particulates and methods of manufacturing and use thereof
02/29/2012CN102365098A Finely pulverized pharmaceutical composition
02/29/2012CN102365092A Burdock fruit extract containing arctigenin at high content and process for producing same
02/29/2012CN102365085A Abuse resistant melt extruded formulation having reduced alcohol interaction
02/29/2012CN102365084A Pharmaceutical dosages delivery system
02/29/2012CN102365083A Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
02/29/2012CN102365082A Method for producing preparations of substances poorly soluble in water
02/29/2012CN102365077A Composition for oral cavity
1 ... 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 ... 2991